Shirin Abbasinejad Enger is tenured Associate Professor in Gerald Bronfman Department of Oncology at McGill University (Montreal, Canada) and Canada Research Chair in Medical Physics. She received her PhD degree from Uppsala University (Uppsala, Sweden) in 2009, and from 2009 to 2011 was a postdoctoral fellow at Université Laval (Quebec City, Canada). She joined McGill University in August 2014 as the head of Novel Patient-Specific Brachytherapy and Detector Technology laboratory. Dr. Abbasinejad Enger’s multidisciplinary research combines basic science with cutting-edge engineering, quantum-optics, scintillating fiber technology, advance radiation dose calculation methods and artificial intelligence to develop radiation delivery systems, dose calculation algorithms, radiotherapy treatment planning software and radiation dosimeters that will enable personalized radiation delivery and imaging. The technology developed by Dr. Abbasinejad Enger’s group aims at achieving high local precision in delivering radiation to the tumour and enable dose escalation in the tumour while simultaneously shield healthy surrounding tissues, i.e., conform the dose distribution to the shape of the tumour, which will increase probability of cure with reduced toxicity and increase quality of life of the patients. Dr. Abbasinejad Enger is the Chair of the Task Group No. 337 on Intensity Modulated and Anisotropic Brachytherapy Sources, member of the Working Group on Brachytherapy Clinical Applications and member of the AAPM/ESTRO/ABG Working Group on MBDCAs in brachytherapy.